Component,Publication Grant Number,Publication Doi,Publication Journal,Pubmed Id,Pubmed Url,Publication Title,Publication Year,Publication Keywords,Publication Authors,Publication Abstract,Publication Assay,Publication Tumor Type,Publication Tissue,Publication Dataset Alias,Publication Accessibility,PublicationView_id,Id,entityId
PublicationView,CA284086,10.1158/1078-0432.ccr-23-2991,Clin Cancer Res,38038687,https://pubmed.ncbi.nlm.nih.gov/38038687,Pancreatic Cancer's PD1-Roadblock: When T-Cell Reinvigoration Is Not Enough,2024,,"Varintra E Lander, David G DeNardo","PD1-blockade combinations in pancreatic ductal adenocarcinoma have been poorly effective, and the underlying reasons for this are unknown. A recent study revealed that chemoradiation plus PD1-blockade reinvigorates tumor-specific T cells; however, this T-cell activation is accompanied with exaggerated NFÎºB signaling, which may limit productive tumor-controlling immunity. See related article by Ali et al., p. 542.",Pending Annotation,Pending Annotation,Pending Annotation,,Restricted Access,38038687,403ecbd2-6454-475f-9e0f-44e2dbff07e5,syn53693596
